| Document Date: 2013-10-08 15:05:43
Open Document File Size: 204,43 KBShare Result on Facebook
City Reference / / Event Product Recall / Product Issues / / Facility Laboratory Tests / Laboratory Tests REVIA / / IndustryTerm metabolic products / healthcare / gas-liquid / heavy machinery / healthcare providers / compliance-enhancing protocol / / MedicalCondition dementia / Suicidality Depression / coma / nausea / hepatitis B / drug dependence / mesothelioma / serious injury / withdrawal syndrome / pre-existing subclinical withdrawal syndrome / liver cirrhosis / diarrhea / visual hallucinations / hepatitis / liver disease / testicular mesotheliomas / alcoholism / clinically significant liver dysfunction / tumors / acute liver injury / alcoholic liver disease / Carcinogenesis / acute hepatitis / erythema / C infection / itching / Lethargy / hepatic injury / vomiting / vascular tumors / chronic basis / respiratory depression / dizziness / liver injury / cough / withdrawal symptoms / Depression / bronchoconstriction / hepatocellular injury / HIV disease / / MedicalTreatment counseling / cardiopulmonary resuscitation / bypass / Pain Management / pharmacotherapy / / Position physician / prescribing physician / PRECAUTIONS General / treating physician / / Product Ultra Rapid Opioid / symptomatology / polyethylene glycol / REVIA / antitussive / naloxone / Opioid / syndrome / disulfiram / Rx / naltrexone hydrochloride / / Technology alpha / drug metabolism / compliance-enhancing protocol / T-1 / Pharmacokinetics / /
SocialTag |
1 REVIA® (naltrexone hydrochloride tablets USP) 50 mg Opioid Antagonist